Objective: Preoperative anemia in elderly patients undergoing surgery is prevalent and associated with adverse events; however, the interaction with other risk factors in patients with chronic limb-threatening ischemia (CLTI) is not well described. The purpose of this study was to assess the association between lower hematocrit (HCT) levels on admission and postoperative outcomes after infrainguinal bypass surgery.
In patients undergoing surgery, it is estimated that nearly one-third suffer from anemia, and this number tends to be even higher in elderly patients and the critically ill. [1] [2] [3] As a marker of illness, anemia is associated with several unfavorable clinical and surgical outcomes. 4 Patients with chronic limb-threatening ischemia (CLTI) undergoing intervention represent a particularly fragile population with depleted reserves due to disease severity and existing comorbidities, and those with low hematocrit (HCT) levels on admission may be at even higher risk. Several studies have demonstrated an association between preoperative anemia and increased postoperative complications in cardiac and noncardiac surgical patients, including mortality, major adverse cardiovascular event (MACE), wound infection, and prolonged hospital stay. [5] [6] [7] [8] [9] [10] [11] [12] [13] In the last few years, however, the focus has shifted more toward the risks and benefits of blood transfusions in patients with peripheral arterial disease. Despite the widespread use of blood transfusions in patients with anemia, several studies have failed to demonstrate a benefit, and in fact, blood transfusions have been shown to be harmful in many clinical settings. [14] [15] [16] [17] [18] Some suggest that it is not the practice of treatment of anemia with blood transfusions that is associated with adverse events but rather the anemia itself that increases the patients' risk of postoperative complications. 4 Interestingly, few reports have evaluated the combined effect of preoperative anemia and blood transfusions, although this is a relevant clinical question for physicians. 19, 20 Detailed risk stratification could provide clinicians valuable guidance in optimizing anemic patients at the time of surgery. Therefore, the aim of this study was to assess whether lower levels of HCT preoperatively were associated with postoperative adverse events in CLTI patients undergoing bypass surgery and to determine whether this risk could be modified by blood transfusions.
METHODS
Data source. A retrospective cohort study was performed using the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) targeted vascular module. NSQIP is a clinical registry designed to improve the quality of surgical care by prospective collection of clinical data that provides reliable and risk-adjusted surgical outcomes up to 30 days. The targeted vascular module captures a subset of patients with additional disease-specific and detailed anatomic characteristics as well as procedure-related outcomes chosen by vascular surgeons. Trained clinical reviewers at each hospital identify potential procedures by reviewing operative case logs, categorize procedures using Current Procedural Terminology codes, and gather data in a standardized fashion according to strict definitions from both the targeted and nontargeted NSQIP. The reliability of NSQIP data collection has been validated previously. [21] [22] [23] More detailed information on this registry is available at www.facs.org/quality-programs/ acs-nsqip. We obtained approval from the Beth Israel Deaconess Medical Center Institutional Review Board without the need for informed consent because this registry contains deidentified data only.
Patients. All patients undergoing infrainguinal bypass between 2011 and 2014 were identified from the targeted vascular module. Emergent cases (n ¼ 389; 7.0%) and those missing preoperative HCT levels (n ¼ 52; 0.9%) were excluded from this study. Preoperative HCT was defined by NSQIP as the last HCT measurement before the index operation, and HCT levels were obtained within 1 month of surgery in 97.4%, with a median of 1 day (interquartile range [IQR], 0-5 days) before surgery. Anemia was considered when the HCT level was 39.0% of blood volume or less, as specified by the World Health Organization. 24, 25 The cohort was subsequently categorized in accordance with their preoperative HCT levels into four arbitrary groups: severe anemia (#29%), moderate anemia (29.1%-34%), mild anemia (34.1%-39%), and no anemia (>39%). As only 1.3% of our study population had an HCT level of <24%, we were unable to construct an additional anemia group.
Variables. Baseline characteristics included demographics, comorbidities, and preprocedural medication. Additional concurrent procedures were evaluated, including endovascular interventions and endarterectomy. Postoperative (30-day) outcome variables were collected for all patients. In accordance with Society for Vascular Surgery efficacy measures, 26 major adverse limb event was defined as major amputation (above or below knee) or major reintervention (new bypass graft; thrombectomy or thrombolysis; or major surgical revision, such as jump or interposition graft), and MACE was defined as death from any cause, myocardial infarction, or stroke. Postoperative blood transfusion was defined as at least one unit of packed red blood cells during surgery or within 72 hours postoperatively and included blood transfused to patients collected by a cell saver. Neither the indication for transfusion nor the HCT levels at the time of transfusion were available in NSQIP. Preoperative blood transfusion was also captured and refers to a transfusion during the 72 hours before surgery. Renal deterioration was defined as an increase in serum creatinine concentration of 2 mg/dL or more and the need for dialysis. Take Home Message: Preoperative anemia was an independent predictor of mortality and major adverse cardiovascular events in 5081 patients undergoing bypass for critical limb ischemia, and the effect was not mitigated by blood transfusion.
The authors suggest that preoperative anemia is associated with increased early mortality and major adverse cardiovascular events after lower extremity bypass surgery and that the effect is not improved with blood transfusion.
considered only for those patients who were originally admitted from home. Variable definitions were not modifiable as they were determined by NSQIP before data collection and can be found in the user guide (www. facs.org/quality-programs/acs-nsqip/program-specifics/ participant-use). P values are relative to this group. Multivariable logistic regression models were constructed for independent associations between anemia and 30-day adverse outcomes, adjusting for similar covariates and confounders. Purposeful selection was used to determine covariates and confounders, which includes variables identified on univariate analysis (P < .10) and clinically relevant variables as described previously. 27 Previous literature suggests that preoperative anemia is one of the strongest predictors of blood transfusion. 14, 15 As such, blood transfusions are likely to act as an intermediate variable between the independent variable (preoperative anemia) and the dependent variable (adverse outcome). Because of this relationship, postoperative blood transfusion was not included as a covariate in the initial multivariable models, which allowed more comprehensive assessment of the direct effect of anemia on outcomes. In addition, a sensitivity analysis was performed to specifically assess effect modification between anemia and postoperative transfusion by forcing an interaction term in the multivariable regression models. Interactions enable the effect of transfusion to vary across the levels of anemia, which provides more detailed predictions. Because blood loss was not captured in this registry, we attempted to account for this in a subgroup analysis excluding those with postoperative blood transfusions, as this selected cohort presumably excludes the patients with significant bleeding. All statistical analyses were performed using SPSS Statistics 23 (IBM Corp, Armonk, NY) with P < .05 considered to be statistically significant. Figures were constructed using Prism 6 (GraphPad, La Jolla, Calif).
RESULTS
A total of 5081 patients with CLTI were included, of which 741 (15%) had severe anemia, 1317 (26%) had moderate anemia, 1516 (30%) had mild anemia, and 1507 (30%) had no anemia.
Baseline and procedure details. The baseline demographics and comorbidities are summarized in Table I . Patients with preoperative anemia were considerably older and less likely to be male and white or to have a history of smoking. Patients with lower HCT levels on admission had more comorbid conditions, such as hypertension, diabetes, chronic heart failure, and renal insufficiency. Preoperative transfusion was more common among those with preoperative low HCT levels (severe, 9.9%; moderate, 4.3%; mild, 0.9%; no anemia, 0.1%; all P < .01). In addition, anemic patients more often had tissue loss compared with those without anemia (severe, 77%; moderate, 69%; mild, 58%; no anemia, 40%; all P < .001).
Regarding operative characteristics, patients with preoperative anemia more often underwent infrapopliteal procedures, whereas femoropopliteal bypass was more common in nonanemic patients (Table II ). In addition, anemic patients were less likely to undergo elective procedures, more frequently had an American Society of Anesthesiologists class $4 (severe, 35%; moderate, 33%; mild, 25%; no anemia, 17%; all P < .001), and had longer procedure times (severe, 247 minutes [IQR, ; moderate, 233 [IQR, 179-315] minutes; no anemia, 221 [165-296] minutes; all P < .001). No differences were observed in the frequency of concurrent procedures between patients with and without anemia.
Postoperative outcomes. Postoperative outcomes are detailed in Table III , A. The 30-day mortality was substantially higher among patients with the lowest HCT levels and declined with increasing HCT levels (severe, 3.1%; moderate, 3.0%; mild, 1.8%; no anemia: 0.7%; all P < .01; Fig 1) . In addition, patients with severe anemia had higher 30-day amputation rates than those without anemia (6.9% vs 3.3%; P < .001). MACE was significantly more common in anemic patients compared with those without anemia (severe, 6.9%; moderate, 6.8%; mild, 5.1%; no anemia, 2.6%; all P < .001). Preoperative anemia was also associated with higher rates of several other postoperative adverse events, including septic shock, renal deterioration, pulmonary complications, unplanned return to the operating room, and unplanned readmissions. Furthermore, postoperative blood transfusions were more frequent in those patients with preoperative low HCT levels (severe, 67%; moderate, 43%; mild, 25%; no anemia, 11%; all P <. 001). No differences were found in major adverse limb events or surgical site infections. [3] [4] [5] [6] [7] days; all P < .001).
In an attempt to account for blood loss and directly assess the effect of anemia, we performed an additional subgroup analysis comparing 30-day outcomes by the level of anemia in those who did not receive postoperative blood transfusions (n ¼ 3482). As detailed in Table III , B, preoperative anemia was again associated with higher rates of mortality, major amputation, MACE, septic shock, and unplanned reoperations on unadjusted analyses. Effect modification. A sensitivity analysis was performed by incorporating effect modification between anemia and postoperative blood transfusion in the multivariable models. Adjusted ORs were compared within anemia categories, with no transfusion as the reference group (Fig 2) . Although the interaction term was significant (P ¼ .001), 30-day mortality was not different in anemic patients in comparing those who received postoperative blood transfusions with those without any blood transfusions and comparable HCT levels. However, in patients with the lowest HCT levels, transfusion demonstrated a trend toward reduced mortality (within severe anemia, transfusion vs no transfusion: OR, 0.6; 95% CI, 0.3-1.5). Mortality was notably more pronounced in nonanemic patients receiving postoperative blood transfusions (OR, 11.6; 95% CI, 3.2-42.3).
In the adjusted analysis, postoperative blood transfusions were associated with MACE in patients with preoperative anemia compared with those who did not receive any blood transfusions (interaction; P < .001). Similarly, MACE was higher in patients with normal HCT levels preoperatively and blood transfusions (OR, 7.4; 95% CI, 3.8-14.5). Of note, transfusion before surgery showed a protective trend in all models (OR < 1.0), such as for mortality (OR, 0.5; 95% CI, 0.2-1.1) and MACE (OR, 0.8; 95% CI, 0.4-1.4). Unadjusted adverse event rates of CLTI patients with different degrees of anemia stratified by postoperative blood transfusion are detailed in the Supplementary Table (online only). 
DISCUSSION
This study demonstrates that mortality increases in CLTI patients undergoing infrainguinal bypass as preoperative HCT level decreases. Mortality within 30 days was 2.8-fold higher in those with severe anemia, and these patients were 1.6 times more likely to undergo a major amputation compared with those without anemia. In addition, even the milder degrees of preoperative anemia were associated with mortality and MACE. Some of these worse outcomes were mitigated by higher transfusion rates in the more anemic patients; however, by analyzing nontransfused patients only in an attempt to account for blood loss, we still demonstrated a higher mortality risk (5.8-fold) associated with severe anemia. Interestingly, MACE was higher in anemic patients who received postoperative blood transfusions compared with those without any blood transfusions, likely reflecting the impact of bleeding or the detrimental effect of perioperative blood transfusions. Mortality in those with preoperative anemia was not affected by blood transfusion.
As in critical care and cardiac surgery, patients with preoperative anemia undergoing vascular interventions have a higher risk of early and late mortality and morbidity. 6 anemia (hemoglobin concentration of <10 g/dL) was associated with 30-day mortality (17.7% vs 5.1%; OR, 3.9; 95% CI, 1.8-8.4) compared with those without anemia. Although they had an older cohort (mean age of 73 years vs 68 years in our study), the mortality rates within 30 days were significantly higher than in this study (anemia, 1.8%-3.1%, vs no anemia, 0.7%), which is likely to be related to sample variability and simply a result of single-institution data and a smaller sample size. Because NSQIP is a large and nationally representative registry, we believe our data provide more generalizable risk estimations. Our data additionally suggest that postoperative blood transfusions were associated with an increased risk of MACE in anemic CLTI patients, whereas transfusions did not affect 30-day mortality, although there was a trend toward lower mortality in patients with severe anemia. In 2010, Wu et al 20 studied a large cohort of 239,286 elderly patients undergoing major noncardiac surgery from the Department of Veterans Affairs NSQIP registry and, using propensity score matching, demonstrated that 30-day mortality was higher in transfused patients with HCT levels of $30% (OR, 1.4; 95% CI, 1.2-1.5) but lower in those with HCT levels of <24% (OR, 0.6; 95% CI, 0.4-0.9) as opposed to patients with comparable HCT levels without transfusion. In a subgroup analysis, the authors accounted for estimated intraoperative blood loss derived from an alternative anesthesiology formula. The HCT threshold for mortality benefit or risk did not change in patients with a blood loss of <500 mL. Yet, in patients with substantial intraoperative blood loss (500-999 mL), mortality was lower in those with HCT values between 30% and 53.9% receiving blood transfusions as opposed to those who did not. Estimated blood loss was not captured in this study, although we attempted to account for this by excluding patients with postoperative blood transfusions, which presumably represents a cohort without significant bleeding. Blood transfusions in the less severely anemic patients are more likely due to blood loss rather than to the sequela of anemia, which CI, Confidence interval; HCT, hematocrit; MACE, major adverse cardiovascular event; OR, odds ratio. Adjusted for age, sex, race, symptom status, smoking, obesity, preoperative transfusion, hypertension, diabetes, congestive heart failure, renal insufficiency, preoperative dialysis, and type of procedure. Boldface values represent significance (P < .05).
a Too few events.
is more likely the indication to transfuse those with severe anemia. Thus, the results of our subgroup analysis suggest that first and foremost, the most severely anemic patients tend to do much worse with significantly lower survival. In addition, transfusions (or the perceived need for transfusions due to bleeding) were associated with a higher risk of adverse events. However, more detailed data with HCT level at the time of transfusion and the indication of ongoing blood loss would be necessary to accurately determine this exact correlation.
In the cardiac and vascular surgery literature, similar unfavorable outcomes associated with transfusions are described in patients undergoing a variety of procedures. [14] [15] [16] 32 The large number of CLTI patients with anemia highlights the need for clinical practice guidelines, yet recommendations from vascular societies currently do not exist. Our observations reflect the lack of a uniform standard to guide the appropriateness of blood product use, as HCT values that triggered transfusions varied greatly. Other medical societies favor restrictive transfusion practices increasingly over liberal approaches. 33, 34 Practice guidelines from the American Association of Blood Banks recommend a restrictive transfusion strategy in postoperative surgical patients as well as in those with pre-existing cardiovascular disease with a hemoglobin concentration threshold of 8 g/dL. 33 Therefore, taking the extensive cardiovascular burden of CLTI patients into consideration, together with the findings of this study, a similarly restrictive approach could be beneficial in the CLTI population. Although we could not incorporate blood loss into the equation, further studies are needed to define an optimal threshold for blood transfusions and to confirm our findings in other registries specific to patients with CLTI. Because perioperative correction of anemia with blood transfusions is not free of risk, investigation of anemia before the surgical incision is appropriate whenever possible. Preoperative screening 4 weeks before an Odds ratio (95% CI) elective intervention may detect anemia in a timely manner, allowing adequate time to respond. Whereas delaying surgery may likely not be the best treatment in CLTI patients, particularly those with tissue loss, a compelling argument may be that preoperative correction of anemia could prevent postoperative blood transfusions, which likely results in a mortality benefit. This is supported by the fact that we observed a protective trend of blood transfusions before surgery in our multivariable models. We believe that this finding emphasizes the need to investigate the appropriate role of preoperative blood transfusions. However, alternative options to treat anemia should be explored where appropriate, such as correction of nutritional deficiencies (iron deficiency reported in 32% of CLTI patients) 35 or erythropoiesis-stimulating agents, although caution should be exercised in considering their use. These measures and more are outlined in the concept of Patient Blood Management, which emphasizes efforts to address and to limit the patient's exposure to blood products. Other important principles involve interdisciplinary blood conservation measures to reduce iatrogenic blood loss, including management of coagulopathy, meticulous techniques, massive hemorrhage protocols, and intraoperative autologous blood conservation, as well as optimization of allogeneic blood product use through strict guidelines. [36] [37] [38] [39] Although blood transfusion continues to be an essential part of care for surgical patients with anemia, implementation of Patient Blood Management in daily clinical practice, which is endorsed by the World Health Organization, may be a necessary extension to the full armamentarium of patient-centered care but transcends one clinical specialty or discipline. Several study limitations should be considered in the interpretation of these data. Whereas this study established an association between preoperative anemia and various adverse events, in a retrospective cohort study, association does not necessarily imply causation. In addition, it remains a challenge to conclude whether anemia is an independent risk factor for worse outcome or a marker of critical illness (eg, renal failure) and disease severity, although we attempted to account for this in the multivariable analysis. With NSQIP registry, we are limited by variable definitions, and unfortunately, we could not account for unmeasured confounders, such as hypotension during the procedure, use of vasopressors, and the units of red blood cells administered, and neither for replacement therapy with fresh frozen plasma or platelets nor for crystalloid fluid support. In addition, HCT levels were obtained before surgery, and postoperative values or values at the time of transfusion were not documented, and neither was the cause of anemia, subsequently precluding their consideration in the multivariable analysis. Because the likelihood of receiving a blood transfusion is high in patients with low HCT levels, together with the low absolute number of patients not transfused at similar levels, identification of an HCT cutoff value for which transfusion may be beneficial was not feasible with our sample size, and larger data sets are needed for this type of analysis. Finally, long-term outcomes could not be assessed with this registry. Nonetheless, despite these limitations, the targeted module provides a large cohort containing granular detail specifically related to patients with CLTI.
CONCLUSIONS
This study highlights the associated risk of preoperative anemia in patients with CLTI as well as the hazards of postoperative blood transfusions as they are intimately related. Adverse events were inversely associated with preoperative HCT levels, and although we could not adjust for estimated blood loss, these data suggest that postoperative blood transfusions do not reducedbut rather increasedpostoperative risks in the less severely anemic patients. Additional studies are warranted to evaluate optimization of HCT before surgery, and because we cannot yet justify widespread use of allogeneic blood transfusions, efforts should be directed toward assessment of an appropriate threshold for perioperative transfusions in CLTI patients undergoing revascularization. 
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